Intravesical MCC for bladder cancer
نویسندگان
چکیده
منابع مشابه
Intravesical Therapy for Superficial Bladder Cancer
The intravesical instillation of therapeutic agents for the treatment of localized bladder cancer began in 1903 when Herring[1] summarized his experience with silver nitrate. Since then, intravesical chemotherapy and immunotherapy have emerged as effective adjuncts to endoscopic resection for superficial transitional cell carcinoma of the bladder. Although advances in the treatment of superfici...
متن کاملIntravesical Therapy for Superficial Bladder Cancer
Transitional cell carcinoma of the bladder remains a significant health problem in the United States. Approximately 54,400 new cases of transitional cell carcinoma were reported in the United States in 1999, and an estimated 12,500 deaths were attributed to this cancer.[1] These statistics have remained relatively unchanged over the last several decades despite improvements in both diagnostic i...
متن کاملTherapies in bladder cancer: intravesical mitomycin-C
The use of intravesical therapy for the treatment of superficial bladder cancer aims to reduce morbidity and mortality by eradicating existing disease, preventing tumor recurrence and attempting to halt tumor progression. Mitomycin-C is a commonly used intravesical treatment option for superficial bladder cancer and was used for the first time by Shida and colleagues in 1967 [1]. It is an antit...
متن کاملIntravesical therapy in superficial bladder cancer.
OBJECTIVE To identify the appropriate characteristics of superficial bladder cancer that allow the physician to predict tumor behavior. METHODS We analyzed 1,745 patients with primary superficial bladder cancer with regard to disease and patient characteristics. RESULTS With the characteristics we found, the population can be described and prognostic factors can be found. Moreover, with the...
متن کاملMycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
Mycobacteria Bovis osteomyelitis is a rare adverse effect after Bacillus Calmette-Guerin (BCG) intravesical therapy. A 62-year-old male presented with acute spinal cord compression three months after completing his second course of therapy for bladder cancer. The first course with intravesical BCG was complicated with an episode of hematuria. He reported intermittent subjective fever for 3 week...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Urology
سال: 2009
ISSN: 1759-4812,1759-4820
DOI: 10.1038/nrurol.2009.64